Treatment of Fuchs Disease: Review of Clinical Trials
DOI:
https://doi.org/10.37497/ijhmreview.v8i1.306Keywords:
Fuchs Endothelial Corneal Dystrophy, Descemet's Membrane, TreatmentAbstract
Background: Fuchs corneal endothelial dystrophy (FECD) is a genetically heterogeneous disease, accompanied by irreparable damage to the corneal endothelium. FECD is characterized by thickening of Descemet's membrane, with accelerated loss of endothelial cells initially in the center of the cornea and later in its periphery. A mosaic defect of the endothelium of the corneal surface in which cells respond with proliferation and migration, resulting in non-uniform abnormalities in size (polymegatism) and variations in hexagonal shape (pleomorphism). The most recent International Classification of Corneal Dystrophies categorizes FECD into two types: 1 - early-onset FECD (rare); and 2 - late-onset FECD (most common). Aim: To carry out a literature review to synthesize the clinical evidence related to the treatments of FECD. Method: Papers were selected in PubMed databases using the following search strategy: fuchs[title] AND dystrophy[title]. Only clinical trials published in the last five years were considered in this review. Results: Eleven articles were selected that adequately discuss treatments and disease management strategies. Synthesis of the Evidence: The main method of treatment for FECD is Descemet's membrane endothelial keratoplasty (DMEK), considered the gold standard for the management of disease. In addition, several tools and strategies capable of improving the parameters related to the procedure, or even allowing the evaluation of the evolution of teaching, are presented.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 International Journal of Health Management Review

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish in this journal agree to the following terms: The author(s) authorize the publication of the text in the journal; The author(s) guarantee that the contribution is original and unpublished and is not in the process of being evaluated by any other journal(s); The journal is not responsible for the opinions, ideas, and concepts contained in the texts, as these are the sole responsibility of their respective author(s); The editors reserve the right to make adjustments to the text in order to ensure that it adheres to the standards of the journal. Authors retain the copyrights and grant the journal the right of first publication, with the article simultaneously licensed under the Creative Commons Attribution License which allows the sharing of the article with the acknowledgment of authorship and initial publication in this journal. Authors are authorized to take additional contracts separately, for the non-exclusive distribution of the version of the article published in this journal (e.g. publication in an institutional repository or as a book chapter), with the acknowledgment of authorship and initial publication in this journal.
Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal webpage) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and citation of published work (See The Effect of Free Access at http://opcit.eprints.org/oacitation-biblio.html)